Leukemia Trial Results
New Drug Shows Promise against Drug-Resistant Leukemias
(Posted: 12/17/2012) - A new drug called ponatinib may be a new treatment option for patients with chronic myeloid leukemia (CML) that is resistant to other therapies, according to results of two early clinical trials.
More Chemotherapy May Help after Initial Treatment for Childhood Leukemia Fails
(Posted: 06/07/2012) - A study suggests that at least some children diagnosed with acute lymphoblastic leukemia who respond poorly to initial chemotherapy may do better if they receive additional chemotherapy rather than a stem cell transplant.
Nilotinib Effective and Safe in Initial Treatment of Chronic Leukemia
(Posted: 12/28/2009, Updated: 09/06/2011) - Preliminary results from a phase III trial testing nilotinib (Tasigna) against imatinib mesylate (Gleevec) as first-line treatment for chronic-phase chronic myelogenous leukemia (CML) indicate that nilotinib is effective and safe as initial treatment for this disease.
Rituximab Improves Outcomes for Patients With Chronic Lymphocytic Leukemia
(Posted: 01/14/2009, Updated: 11/05/2010) - Advanced chronic lymphocytic leukemia patients who received the monoclonal antibody rituximab in addition to standard chemotherapy with fludarabine and cyclophosphamide (FC) had outcomes far better than those patients who received FC alone, according to studies presented December 2008 at the American Society of Hematology meeting.
Drug Protects Heart in Children Receiving Common Chemotherapy
(Posted: 09/24/2010) - The drug dexrazoxane, which can protect heart tissue from the oxidative damage caused by doxorubicin and other anthracycline drugs, reduced long-term heart damage in children undergoing treatment for high-risk acute lymphoblastic leukemia (ALL) but did not affect treatment efficacy, according to a study published September 15, 2010, in Lancet Oncology.
(Posted: 12/17/2012) - A new drug called ponatinib may be a new treatment option for patients with chronic myeloid leukemia (CML) that is resistant to other therapies, according to results of two early clinical trials.
More Chemotherapy May Help after Initial Treatment for Childhood Leukemia Fails
(Posted: 06/07/2012) - A study suggests that at least some children diagnosed with acute lymphoblastic leukemia who respond poorly to initial chemotherapy may do better if they receive additional chemotherapy rather than a stem cell transplant.
Nilotinib Effective and Safe in Initial Treatment of Chronic Leukemia
(Posted: 12/28/2009, Updated: 09/06/2011) - Preliminary results from a phase III trial testing nilotinib (Tasigna) against imatinib mesylate (Gleevec) as first-line treatment for chronic-phase chronic myelogenous leukemia (CML) indicate that nilotinib is effective and safe as initial treatment for this disease.
Rituximab Improves Outcomes for Patients With Chronic Lymphocytic Leukemia
(Posted: 01/14/2009, Updated: 11/05/2010) - Advanced chronic lymphocytic leukemia patients who received the monoclonal antibody rituximab in addition to standard chemotherapy with fludarabine and cyclophosphamide (FC) had outcomes far better than those patients who received FC alone, according to studies presented December 2008 at the American Society of Hematology meeting.
Drug Protects Heart in Children Receiving Common Chemotherapy
(Posted: 09/24/2010) - The drug dexrazoxane, which can protect heart tissue from the oxidative damage caused by doxorubicin and other anthracycline drugs, reduced long-term heart damage in children undergoing treatment for high-risk acute lymphoblastic leukemia (ALL) but did not affect treatment efficacy, according to a study published September 15, 2010, in Lancet Oncology.
